Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma

Table 1 Clinicopathological features of patients with hepatocellular carcinoma

Variable	n	Percentage (%)
Total	182	100.0
Age (years)1
< 49	98	53.8
≥ 49	84	46.2
Gender
Male	135	74.2
Female	47	25.8
Race
Han	89	48.9
Others	93	51.1
Smoking
No	138	75.8
Yes	44	24.2
Drinking
No	135	74.2
Yes	47	25.8
HBsAg
Negative	63	34.6
Positive	119	65.4
Anti-HCV
Negative	149	81.9
Positive	33	18.1
AFP
Negative	64	35.2
Positive	118	64.8
AFB1 exposure
Low	75	41.2
High	107	58.8
Tumor size
≤ 5 cm	56	30.8
> 5 cm	126	69.2
ES grade
Low	94	51.6
High	88	48.4
TNM stage
I	30	16.5
II	78	42.9
III	74	40.7
Liver cirrhosis
No	56	30.8
Yes	126	69.2
MVD
Low	90	49.5
High	92	50.5
PVTT
Negative	127	69.8
Positive	55	30.2
MVI
Negative	116	63.7
Positive	66	36.3

¹Age was grouped according to the average age of patients with hepatocellular carcinoma (49.52 10.79 years old).

HCV: Hepatitis C virus; AFP: Alpha fetoprotein; AFB1: Aflatoxin B1; ES: Edmondson and Steiner; TNM: Tumor node metastasis; MVD: Microvessel density; PVTT: Portal vein tumor thrombus; MVI: Microvessel infiltration.